Selarsdi, ustekinumab-aekn (biosimilar to Stelara)
Named-patient access overview. Selarsdi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Selarsdi
Selarsdi (ustekinumab-aekn) is a biosimilar to Stelara, developed by Alvotech and commercialized in the United States by Teva Pharmaceuticals. It was approved by the US FDA in 2024 for moderate-to-severe plaque psoriasis in adults and pediatric patients six years and older, and for active psoriatic arthritis in adults, following the reference product's approved indication scope.
The molecule is a fully human monoclonal antibody that binds the shared p40 subunit of interleukin-12 and interleukin-23, blocking downstream signaling on T cells, NK cells, and antigen-presenting cells implicated in psoriatic inflammation. Selarsdi is administered subcutaneously, typically with a loading regimen followed by maintenance dosing every twelve weeks.
Selarsdi may be accessible to international patients through Named Patient Program or personal-import pathways. As a biosimilar to Stelara, it is indicated within the reference product's approved scope and is not a novel molecule.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Selarsdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Selarsdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Selarsdi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Selarsdi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Selarsdi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Selarsdi if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Selarsdi for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Selarsdi through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Selarsdi. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Selarsdi through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Selarsdi to a patient?
Reserve Meds sources Selarsdi from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Selarsdi cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Selarsdi?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.